免疫功能低下宿主黏膜皮肤单纯疱疹病毒感染的静脉用阿昔洛韦多中心协作试验。

Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host.

作者信息

Meyers J D, Wade J C, Mitchell C D, Saral R, Lietman P S, Durack D T, Levin M J, Segreti A C, Balfour H H

出版信息

Am J Med. 1982 Jul 20;73(1A):229-35. doi: 10.1016/0002-9343(82)90097-3.

Abstract

Intravenous acyclovir was evaluated in the treatment of 97 immunocompromised patients with mucocutaneous herpes simplex virus infection in a randomized, double-blind, placebo-controlled trial. Acyclovir recipients had significantly shorter periods of virus shedding (p less than 0.0002) and lesion pain (p less than 0.01), and more rapid lesion scabbing (p less than 0.004) and lesion healing (p less than 0.04). The most common adverse reaction was a low incidence of peripheral vein irritation; no serious toxicity could be definitely attributed to acyclovir treatment even in these seriously ill patients. Intravenous acyclovir offers both safe and effective treatment for mucocutaneous herpes simplex virus infection in the immunocompromised host.

摘要

在一项随机、双盲、安慰剂对照试验中，对97例免疫功能低下的黏膜皮肤单纯疱疹病毒感染患者进行了静脉注射阿昔洛韦治疗的评估。接受阿昔洛韦治疗的患者病毒排出期显著缩短（p<0.0002），皮损疼痛时间显著缩短（p<0.01），皮损结痂和愈合更快（分别为p<0.004和p<0.04）。最常见的不良反应是外周静脉刺激发生率低；即使在这些重症患者中，也不能明确将任何严重毒性归因于阿昔洛韦治疗。静脉注射阿昔洛韦为免疫功能低下宿主的黏膜皮肤单纯疱疹病毒感染提供了安全有效的治疗方法。